Orlistat: profile and news

Low-dose Orlistat helps in fat war -- but heed warning  16 May 2006
Recently one of them, Orlistat, moved a step closer to becoming available without a prescription. use. This is a lower dose than the prescription form. ... - Miami Herald,

From the analyst's couch: Anti-obesity therapies  May 4, 2006
Orlistat (Xenical; Roche) reduces weight by limiting caloric intake through inhibition of the lipase-mediated breakdown of fat in the gastrointestinal tract. ... - Nature.com (subscription),

Healthcare: At a Glance - Government Launches Weight-Control ...  May 12, 2006
Roche's Xenical (aka orlistat), Abbott's Reductil (sibutramine) and Sanofi-Aventis's Acomplia (rimonabant) are the three main anti- obesity pills. ... - International News Service,

Another Weightloss Pill Poses Health Risks  May 3, 2006
The group said a December 2005 study confirmed earlier company data showing Xenical, known generically as orlistat, can cause abnormal cell growth in the ... - Emediawire (press release),

Allergan's Weight-Loss Bands Beat Diet, Exercise, Study Says  May 1, 2006
The non-surgical program was run by a physician and included behavioral modifications, a low-calorie diet and drug therapy with orlistat, sold as Xenical by ... - Bloomberg

The Heavy Burden of Stereotyping  May 8, 2006
Sally Squires discusses the weight-loss drug Orlistat in a February 2006 interview, on the nationally syndicated radio program, 'The Satellite Sisters' on ABC ... - Washington Post,

Stomach surgery may have a role in moderate obesity  May 2, 2006
...weight. Forty patients were randomized to diet, exercise, and treatment with the weight loss drug, orlistat, over a 6-month period. ... - Reuters.uk,

Australian LAP-BAND Study Passes Over Low-Carb Comparison  May 3, 2006
...between 30-35 and split them into two groups: 1) physician-directed, very low-calorie diet in combination with the weight loss pill orlistat, lifestyle change ... - The Common Voice,

Gastric Banding May Help In Moderate Obesity  May 2, 2006
Half of patients were randomized to diet, exercise, and treatment with the weight loss drug, orlistat, over a 6-month period under regular observance. ... - All Headline News

LAP-BAND Patients Lose Significantly Greater Amounts of Initial ...  May 1, 2006
...non-surgical program was physician directed and consisted of behavioral modifications, a very low calorie diet and pharmacotherapy with orlistat plus education ... - PR Newswire (press release),

Gastric Banding Effective for Mild to Moderate Obesity  May 1, 2006
Forty patients were randomized to the nonsurgical group, which included a very-low-calorie diet, advice for exercise, and treatment with orlistat over a 6 ... - Medscape (subscription)

Glaxo Launches Weight-Loss Website Prior to FDA Action on Diet ...  Apr 26, 2006
...in order to post comments or questions and take part in surveys -- is collecting thousands of email addresses for use in its orlistat marketing campaign. ... - Acomplia Report,

Cutting weight without the knife  Apr 23, 2006
FDA drugs that will be administered to the subjects are one of two medications: Sibutramine, which acts as an appetite suppressant, and Orlistat, which blocks ... - University at Buffalo The Spectrum,

AACE: Insulin Not Sodium May Be Hypertension's Bad Actor  Apr 28, 2006
...summer," he said. "We will be comparing the high fat, no-calorie-restriction diet, to a low fat diet plus Xenical (orlistat).". Asked to ... - MedPage Today,

Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.

Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.

Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.

Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time.

Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.

Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).

Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.

Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.

Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.

Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.